MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 1002-1008

  Paquette, Melanie A ^a,b,c   Anderson, Akari M ^a   Lewis, Jason R ^a   Meshul, Charles K ^a,b   Johnson, Steven W ^a,b   Paul Berger, S ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

6 Hydroxydopamine; Dyskinesia; NMDA; Parkinson's disease; Rats

Indexed keywords

AMANTADINE; DEXTROMETHORPHAN; DIZOCILPINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSKINESIA; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; THERAPY EFFECT;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TIME FACTORS;

EID: 77950935474     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.01.003     Document Type: Article

References (53)

1. Baptista T., López M.E., Teneud L., Contreras Q., Alastre T., de Quijada M., Araujo de Baptista E., Alternus M., Weiss S.R., Musseo E., Páez X., Hernández L. Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral endocrine and neurochemical correlates. Pharmacopsychiatry 1997, 30:43-54.
2. Bhidayasiri R., Truong D.D. Motor complications in Parkinson disease: clinical manifestations and management. Journal of the Neurological Sciences 2008, 266:204-215.
3. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. European Journal of Neuroscience 2006, 23:2669-2676.
4. Bishop C., Krolewski D.M., Eskow K.L., Barnum C.J., Dupre K.B., Deak T., Walker P.D. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. Journal of Neuroscience Research 2009, 87:1645-1658.
5. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Movement Disorders 1998, 13:798-802.
6. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clinical Neuropharmacology 1994, 17:73-82.
7. Carey R.J., Dai H., Krost M., Huston J.P. The NMDA receptor and cocaine: evidence that MK-801 can induce behavioral sensitization effects. Pharmacology Biochemistry & Behavior 1995, 51:901-908.
8. Cenci M.A., Lee C.S., Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. European Journal of Neuroscience 1998, 10:2694-2706.
9. Chan D.K., Cordato D.J., O'Rourke F. Management for motor and non-motor complications in late Parkinson's disease. Geriatrics 2008, 63:22-27.
10. Chase T.N., Oh J.D., Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology 2000, 247(Suppl. 2):II36-II42.
11. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds. Behavioural Brain Research 2007, 179:76-89.
12. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., Chase T.N., Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders 2001, 16:515-520.
13. Delfino M., Kalisch R., Czisch M., Larramendy C., Ricatti J., Taravini I.R., Trenkwalder C., Murer M.G., Auer D.P., Gershanik O.S. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 2007, 32:1911-1921.
14. Dunnett S.B., Torres E.M., Annett L.E. A lateralised grip strength test to evaluate unilateral nigrostriatal lesions in rats. Neuroscience Letters 1998, 245:1-4.
15. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
16. Dupre K.B., Eskow K.L., Negron G., Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Research 2007, 1158:135-143.
17. Dupre K.B., Eskow K.L., Steiniger A., Klioueva A., Negron G.E., Lormand L., Park J.Y., Bishop C. Effects of coincident 5-HT (1A) receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berlin) 2008, 199:99-108.
18. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT (1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacology Biochemistry & Behavior 2007, 87:306-314.
19. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Movement Disorders 2007, 22:1379-1389.
20. Frantz K., Van Hartesveldt C. Locomotion elicited by MK-801 in developing and adult rats: temporal environmental and gender effects. European Journal of Pharmacology 1999, 369:145-157.
21. Fredriksson A., Danysz W., Quack G., Archer T. Co-administration of memantine and amantadine with sub/suprathreshold doses of l-Dopa restores motor behaviour of MPTP-treated mice. Journal of Neural Transmission 2001, 108:167-187.
22. Gaikwad R.V., Gaonkar R.K., Jadhav S.A., Thorat V.M., Jadhav J.H., Balsara J.J. Involvement of central serotonergic systems in dextromethorphan-induced behavioural syndrome in rats. Indian Journal of Experimental Biology 2005, 43:620-625.
23. Gaytan O., Nason R., Alagugurusamy R., Swann A., Dafny N. MK-801 blocks the development of sensitization to the locomotor effects of methylphenidate. Brain Research Bulletin 2000, 51:485-492.
24. Goto S., Korematsu K., Inoue N., Yamada K., Oyama T., Nagahiro S., Ushio Y. N-methyl-d-aspartate receptor antagonist MK-801 induced circling behavior in rats with unilateral striatal ischemic lesions or nigral 6-hydroxydopamine lesions. Acta Neuropathologica 1993, 86:480-483.
25. Haggerty G.C., Brown G. Neurobehavioral profile of subcutaneously administered MK-801 in the rat. Neurotoxicology 1996, 17:913-921.
26. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Research 1994, 633:337-342.
27. Jaunarajs K.L., Dupre K.B., Steiniger A., Klioueva A., Moore A., Kelly C., Bishop C. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. NeuroReport 2009, 20:1265-1269.
28. Johnston T.H., Lee J., Gomez-Ramirez J., Fox S.H., Brotchie J.M. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Experimental Neurology 2005, 191:243-250.
29. Lindner M.D., Plone M.A., Francis J.M., Emerich D.F. Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet. Brain Research Bulletin 1996, 39:367-372.
30. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. European Journal of Neuroscience 2002, 15:120-132.
31. Lundblad M., Usiello A., Carta M., Hkanssond K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental Neurology 2005, 194:66-75.
32. Marin C., Jimenez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 2000, 36:267-274.
33. Marin C., Aguilar E., Rodríguez-Oroz M.C., Bartoszyk G.D., Obeso J.A. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (Berlin) 2009, 204:241-250.
34. Mathé J.M., Nomikos G.G., Schilström B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. Journal of Neuroscience Research 1998, 51:583-592.
35. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of Neurology 1999, 56:1383-1386.
36. Monville C., Torres E.M., Dunnett S.B. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Research Bulletin 2005, 68:16-23.
37. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131(Pt 12):3380-3394.
38. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. Journal of Neural Transmission General Section 1993, 91:13-25.
39. Paquette M.A., Brudney E.G., Putterman D.B., Meshul C.K., Johnson S.W., Berger S.P. Sigma ligands but not N-methyl-d-aspartate antagonists reduce levodopa-induced dyskinesias. NeuroReport 2008, 19:111-115.
40. Paquette M.A., Foley K., Brudney E.G., Meshul C.K., Johnson S.W., Berger S.P. The sigma-1 antagonist BMY-14802 inhibits l-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology 2009, 204:743-754.
41. Paquette M.A., Marsh S.T., Hutchings J.E., Castañeda E. Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior. Behavioural Brain Research 2009, 200:197-207.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
43. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., Agid Y. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Movement Disorders 2001, 16:708-713.
44. 3H]dopamine turnover in striatum and frontal cortex in vivo linked to glutamate receptor antagonism. Journal of Neurochemistry 1998, 70:1979-1985.
45. Robinson S., Krentz L., Moore C., Meshul C.K. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats. Synapse 2001, 42:54-61.
46. Spooren W.P., Gasparini F., Bergmann R., Kuhn R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod., locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. European Journal of Pharmacology 2000, 406:403-410.
47. Taylor J.L., Bishop C., Ullrich T., Rice K.C., Walker P.D. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 2006, 50:761-768.
48. Taylor J.L., Bishop C., Walker P.D. Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacology Biochemistry & Behavior 2005, 81:887-893.
49. Verhagen Metman L., Blanchet P.J., van den Munckhof P., Del Dotto P., Natté R., Chase T.N. A trial of dextromethorphan in parkinsonian patients with motor response complications. Movement Disorders 1998, 13:414-417.
50. Verhagen Metman L., Del Dotto P., Blanchet P.J., van den Munckhof P., Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in PD. Amino Acids 1998, 14:75-82.
51. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50:1323-1326.
52. Verhagen Metman L., Del Dotto P., Natté R., van den Munckhof P., Chase T.N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998, 51:203-206.
53. Zhang J., Chiodo L.A., Freeman A.S. Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Research 1992, 590:153-163.